| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/26/2026 | ±2.7% | -1.6% | over-priced |
| 05/20/2026 | ±4.3% | +1.3% | over-priced |
| 02/25/2026 | ±2.4% | +1.4% | over-priced |
| 11/19/2025 | ±4.2% | +2.9% | over-priced |
| 08/27/2025 | ±2.9% | -0.1% | over-priced |
| 05/28/2025 | ±3.0% | -0.5% | over-priced |
| 02/26/2025 | ±4.7% | +3.7% | over-priced |
| 11/20/2024 | ±3.5% | -0.8% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2027 | $2.46 | $96.2B | $59.7B |
| Q1 FY2027 | $2.39 | $81.6B | $58.3B |
| Q4 FY2026 | — | $68.1B | $43.0B |
| Q3 FY2026 | $1.30 | $57.0B | $31.9B |
NVDA (NVDA) reports in 29 days, with the next report estimated for 11/25/2026. Across the last 8 reports, options priced an average ±3.5% earnings move while the stock actually moved 1.5% on average — the market has systematically over-priced NVDA's earnings risk. Fundamentals into the print: EPS up 127.8% year-over-year, revenue up 105.9%. QuantLogix's live 5-factor engine currently reads NVDA as a buy at 71/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →